Kornimate/medical-research-clean huggingface dataset:
impact of marketing of alcohol products on young people

Conditions: Alcoholism

Summary: impact of marketing of alcohol products on young people

responsible for 3.3 million deaths worldwide, alcohol consumption causes diseases (liver cirrhosis, cancers, etc.) and social problems (injuries, road accidents, alcohol dependence, etc.). with one of the highest consumption rate in europe, alcohol is the second cause of avoidable mortality in france after tobacco (49.000 alcohol attributable deaths in 2009) and its social cost is estimated to 120 billion euros. french teenage population is particularly associated with heavy drinking patterns: in 2014, 49% of 17-year olds declared heavy episodic drinking. in that regard, several measures are recommended by health actors to combat this issue: minimum unit pricing, sales ban to minor, low blood alcohol concentration for drivers, etc. a specific measure concerns alcohol advertising restrictions. some countries implemented alcohol advertising regulation laws (poland, sweden, finland, estonia, etc.), including france with the evin law passed in 1991. this french law mandates advertising (and packaging) content to strictly convey factual information and objective qualities of alcohol products and thus bans attractive ads based on image and lifestyle evocations (seduction, power, etc.). the objective of this research is to investigate whether statutory framework for alcohol advertising (e.g., evin law) can effectively protect people against misleading, suggestive, and appealing content. little research has been conducted on this topic in spite of who's recommendations (most research has explored the influence of exposure to ads but not the impact of content).

Eligibility criteria:
inclusion criteria: * volunteer males * aged 18-25 * right-handed * persons that consume alcohol : " light drinkers " or "heavy drinkers" (defined with the audit scale, scores between 1 to 7) * written consent and agreement consent will be given * affiliated to the french social insurance exclusion criteria: * color-blind persons * misuse of psychoactive products (except tobacco) (cannabis : no regular consumers -more than 10 times per month ; no users of other illicit drugs - even for occasional consumption) * non fluent french speaking persons (people who couldn't understand instructions or asked questions) * persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty related to the mri: * cardiac pacemaker or implanted defibrillator * cochlear implant * peripheral or neuronal stimulator * intra-ocular or brain metallic foreign bodies * any other contraindications to mri
creation of a monocentric cohort of patients treated for acne at the nantes university hospital

Conditions: Acne

Summary: with 24 million results associated with google's searchon keywords "severe acne", pr dreno's team understand better thatthis disease, which affects many french people, is a real concern of public health and not a "forced evil" of the adolescent period, which will eventually resolve itself. acne does not affect the vital prognosis, but its psychosocial impact is major and should not be underestimated. paradoxically, despite the high prevalence of acne, few quality epidemiological studies have been published. physicians are often helpless when faced with patients' questions. they often need a lot of explanations, especially on the factors aggravating this dermatosis, which greatly affects their quality of life. this cohort, the first of its kind in france, will determine the predictive factors of therapeutic response, endogenous and environmental factors impacting on the severity of acne assess the quality of life and psychological impact of acne patients, determine the patient's course of care and the associated costs. pr dreno's team will also build up a bio collection (bacteriological samples).

all patients going for the first time in specialized consultation "acne" at nantes university hospital , and who meet the inclusion criteria will be included in the copacne cohort. inclusion will take place at the first consultation, after information and agreement of the patient and, if applicable, his or her legal representatives. the frequency of each patient's follow-up visits will be determined on a case-by-case basis according to the patient's medical needs (generally, the interval between 2 visits is between 1 and 4 months).

Eligibility criteria:
inclusion criteria: * patient with acne * patient (or parents/guardians for minors) who are not opposed to participating in the cohort. * subjects affiliated to an appropriate health insurance exclusion criteria: * dermatosis of the face other than acne * refusal to participate by the minor or parent/guardian * adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)

Keywords: acne cohort prospective risk factors
intravenous magnesium sulfate in aneurysmal subarachnoid haemorrhage (imash)

Conditions: Subarachnoid Hemorrhage

Summary: the imash trial is a simple, randomized, double-blinded, placebo-controlled, multi-center trial to answer the question: "does intravenous magnesium sulfate improve clinical outcome after aneurysmal subarachnoid hemorrhage?"

vasospasm worsen outcome in patients with aneurysmal subarachnoid hemorrhage (asah). magnesium is known to dilate cerebral arteries and to block n-methyl-d-aspartate receptors in the injured neurons. intravenous magnesium may prevent vasospasm after subarachnoid hemorrhage and may protect neurons against damage during established vasospasm. the imash trial is a randomized, placebo-controlled, double-blinded, multi-center trial to evaluate the effect that intravenous magnesium sulfate infusion on the clinical outcome of patients with aneurysmal subarachnoid haemorrhage. methods: after obtaining randomisation code: * start mgso4 20 mmol over 30 minutes, followed by infusion of 80 mmol/day or equivalent volume of saline within 48 h after onset of symptom, * study drug to be infused for 14 days from the day of hemorrhage (regarded as day 0). * measure plasma magnesium concentration daily and perform transcranial doppler to monitor blood flow velocities of both middle cerebral arteries and extracranial segment of the internal carotid arteries. * plasma magnesium concentration in the iv mgso4 group should be raised to 2.0-2.5 mmol/l or twice the serum baseline level. patients that are randomized to saline infusion will only have their magnesium levels normalized if there is a clinical indication to do so. outcome assessment primary outcome: extended glasgow outcome scale at six months secondary outcome: incidence of clinical vasospasm, barthel index; modified rankin score, modified national institute of health stroke score, mca velocities, other major complications study duration: 6 years with a refined sample size of 340 after analysis of pilot study data; with planned interim analysis.

Eligibility criteria:
inclusion criteria: * asah (as indicated by ct scan or lumbar puncture and an intracranial aneurysm confirmed by computer tomographic or conventional angiography) * within 48 hrs of ictus (hemorrhage event) exclusion criteria: * pregnancy * major renal, hepatic or pulmonary disease * major cardiac disease or recent myocardial infarct (\< 6 months) * age less than 18 years * moribund condition on admission (defined as a patient that is in such a poor clinical condition that further active neurosurgical management would not be anticipated)

Keywords: subarachnoid hemorrhage magnesium sulfate
pharmacokinetic, bioavailability, and safety study of cov155 administered in healthy subjects under fed and fasted conditions

Conditions: Pharmacokinetics

Summary: a single center, single dose, open-label, randomized, 3-period, 6-sequence, crossover study conducted in normal healthy subjects to evaluate the effect of a high- and low-fat meal on the pharmacokinetics (pk), bioavailability (ba), and safety of cov155.


Eligibility criteria:
inclusion criteria: 1. males and/or non-pregnant, non-lactating or postmenopausal females, between 18 and 55 years of age with a body mass index ≥ 19 and ≤ 30 kg/m2. 2. all subjects biologically capable of having children must agree and commit to the use acceptable method(s) of birth control. exclusion criteria: 1. ecg abnormalities or lab values greater than 2 times the upper limit of normal. 2. positive test results for human immunodeficiency virus (hiv), hepatitis b (hbsag), or hepatitis c (igg). 3. positive urine test results for drugs of abuse or history of drug/alcohol abuse. 4. use of marijuana, illicit drugs or nicotine-containing products. 5. donated or had significant loss of whole blood. 6. taken any prescription or nonprescription drugs, vitamins, minerals, or dietary/herbal supplements. 7. history of abdominal and/or pelvic surgery, cholecystectomy, gastric bypass or gastric band surgery, or cardiothoracic surgery. 8. history of anxiety, tension, agitation, psychiatric disorders, psychosis, or depression requiring hospitalization, psychotherapy, and/or medication. 9. history of acute or chronic gastrointestinal disease or any condition that may interfere with the absorption, distribution, metabolism or excretion of the study treatment. 10. history of seizures or diagnosis of epilepsy or other seizure disorder. 11. history or laboratory evidence of bleeding or clotting disorder or condition. 12. history or laboratory evidence of malignancy, stroke, diabetes, cardiac, renal, liver, and chronic pulmonary disease. 13. have or have a history of hay fever or seasonal allergies requiring over-the-counter or prescription medications.
non-compliance on treatment among diabetic students at sohag university

Conditions: Diabetes Mellitus, Type 1

Summary: a cross-sectional study on diabetic students in sohag university will be conducted to collect data about factors affecting compliance and adherence to diabetes treatment and its impact on development of complications.

personal interviews with diabetic students through a questionnaire : 1. to determine factors affecting non compliance on treatment among diabetic students. 2. to detect relation between non compliance on treatment and development of complications.

Eligibility criteria:
inclusion criteria: * diabetic students at sohag university age from 17 to 25 exclusion criteria: * healthy students * students in other universities
laparoscopic versus open appendectomy? let the patient decide

Conditions: Appendicitis

Summary: this protocol examines choice where it pertains to choosing between two standard methods for appendectomy, laparoscopic or open procedures, and the affect that "cost" of the appendectomy has upon choice. children admitted with a diagnosis of uncomplicated appendicitis will be consented to participate in a study in which the patient can choose between laparoscopic or open appendectomy procedures. those that agree to review a consent form will be randomly placed into one of two groups. the two groups consist of one in which the consent form includes "cost information for each operative procedure" in the comparison between the procedures, and the other group receives a consent form that does not include "cost information for each operative procedure". both groups also view a short, group specific, computerized presentation that describes each procedure. the hypothesis is that those patients given a choice between two similar surgical procedures and are provided with "cost information" will more often choose the less expensive surgical procedure than those that do not have information related to the cost of the surgical procedures.


Eligibility criteria:
inclusion criteria: * acute appendicitis exclusion criteria: * age 18 or older * imaging positive for perforation; ultrasound or ct scan * pain for greater than 2 days * children with a body mass index \> 95% for age and sex * surgeon decision for non-equivalent procedure based on patient presentation

Keywords: surgical choice cost of care decision making health care health care cost pediatric children appendicitis patient satisfaction
alogliptin tablets special drug use surveillance type 2 diabetes mellitus: combination therapy with sulfonylurea

Conditions: Surveillance

Summary: the purpose of this study is to examine the safety and efficacy of long-term combination therapy with alogliptin (nesina) and sulfonylurea in participants with type 2 diabetes mellitus who responded inadequately to treatment with sulfonylurea in addition to diet therapy and exercise therapy.

this is a special drug use surveillance on long-term use of alogliptin with a 1-year (12-month) observational period, designed to investigate the safety and efficacy of long-term combination therapy with alogliptin and sulfonylurea in participants with type 2 diabetes mellitus in a routine clinical setting. participants with type 2 diabetes mellitus who responded inadequately to treatment with sulfonylurea in addition to diet therapy and exercise therapy will be enrolled in this study. the planned sample size is 1,000. the usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily.

Eligibility criteria:
inclusion criteria: * participants who did not adequately respond to the following treatment • treatment with sulfonylurea in addition to diet therapy and exercise therapy exclusion criteria: 1. participants with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus (these participants require prompt adjustment of hyperglycemia by fluid infusion and insulin, and hence use of nesina is not appropriate). 2. participants with severe infection, pre- or post-operative participants, or participants with serious traumatic injury (blood glucose control by insulin injection is desirable for these participants, and hence use of nesina is not appropriate). 3. participants with a history of hypersensitivity to any ingredient of nesina.

Keywords: drug therapy
comparison of ultrasound versus radiography for diagnosis of nasal fractures

Conditions: Nasal Fracture

Summary: the standard imaging procedure to diagnose a nasal fracture still is radiography (lateral nasal view and occipitomental view). but technological advances in ultrasonography during the last few decades have made high-resolution ultrasound devices available to the majority of medical centers. it has been shown that the bony structures of the nose can be well examined by ultrasound in the last few years. the hypothesis: "is ultrasound of equal diagnostic accuracy in diagnosing nasal fractures as radiography" is being tested in the investigators' study. patients with suspected nasal fracture undergo ultrasound examination in addition to the routine x-ray imaging. after completion of treatment, the readings of both ultrasound and radiographs are compared in terms of sensitivity and specificity to diagnose nasal fractures.


Eligibility criteria:
inclusion criteria: * suspected nasal fracture exclusion criteria: * further fractures * pregnancy * unstable condition * refusal to undergo ultrasound examination
safety of artemether - lumefantrine, and other malaria drugs and their effect on the auditory function

Conditions: Malaria; Falciparum

Summary: this study is not enrolling patients in the usa. to evaluate the effects of artemether/ lumefantrine on the auditory function.


Eligibility criteria:
inclusion criteria * 12 years of age or older * p. falciparum parasitemia between 50 and 100,000 parasites/μl * history of fever or presence of fever (temperature ≥ 37.5°c) exclusion criteria * signs/symptoms of severe/complicated malaria * ingestion of various antimalarial drugs, or antibiotics in the previous 2 weeks to 2 months * history of any drug-related hearing impairment. * abnormal hearing function at study entry * exposure to sustained loud noises, by self-report, within the past 24 hours. -- present ear problems (other protocol-defined inclusion/exclusion criteria may apply.)

Keywords: malaria hearing co-artemether auditory plasmodium falciparum marsh fever plasmodium infections remittent fever paludism artemether artemisinins benflumetol lumefantrine
effect of the association of berberine fitosoma® and monacolin k monakopure® on glyco-metabolic parameters in dysglycemic and dyslipidemic patients.

Conditions: Dyslipidemias; Dysglycemia

Summary: the objective of this study is to evaluate the effectiveness of the association berberina fitosoma® and monacolin k monakopure® (berberol® k supplement) compared to placebo on glucidic and lipid parameters in subjects with fasting blood glucose (fpg) values between 100 and 125 mg/dl and with total cholesterol (tc) values ≥ 200 mg/dl.

the objective of this study is to evaluate the effectiveness of the association berberina fitosoma® and monacolin k monakopure® (berberol® k supplement) compared to placebo on glucidic and lipid parameters in subjects with fasting blood glucose (fpg) values between 100 and 125 mg/dl and with total cholesterol (tc) values ≥ 200 mg/dl.

Eligibility criteria:
inclusion criteria: * overweight or obese subjects \[according to body mass index (bmi)\] * fasting plasma glucose value between 100 and 125 mg/dl, with impaired fasting glucose or impaired glucose tolerance confirmed with oral glucose tolerance test (ogtt) * total cholesterol values ≥ 200 mg/dl exclusion criteria: * patients with neoplastic and liver diseases, renal failure * patients with type 1 or 2 diabetes mellitus * pregnant or breastfeeding women * hypersensitivity to any of the ingredients * therapy with lipid-lowering drugs * use of products containing red yeast rice
cuff shape and postoperative sore throat in breast cancer patients

Conditions: Breast Cancer; Postoperative Sore Throat; Subglottic Airway Injury; Endotracheal Tube Cuff

Summary: this study aimed to evaluate the impact of endotracheal tube cuff shapes on the incidence and severity of postoperative sore throat

postoperative sore throat (post) is a minor complication after general anesthesia with tracheal intubation but may negatively affect patient satisfaction and postoperative recovery. due to the multifactorial nature, the detailed mechanism of post has not been fully understood. however, mucosal irritation and inflammation related to the presence of an ett within the trachea appear to be one of the primary causes of post, which may involve elements including the tube size, intracuff pressure, and duration of intubation. in addition, the cuff design of an ett, which can determine the contact area between the cuff and the tracheal mucosa, is reported to affect the development of post. this study aimed to evaluate the impact of endotracheal tube (ett) cuff shapes on the incidence and severity of post. additionally, we investigated the influence of ett cuff shapes on the degree of subglottic injury following ga for breast cancer surgery.

Eligibility criteria:
inclusion criteria: * female patients scheduled for elective breast cancer surgery performed in the supine position requiring tracheal intubation exclusion criteria: * age \ 80 years * diseases or anatomic abnormalities in the neck, larynx, or pharynx * combined surgery such as breast reconstruction * active pulmonary disease * morbid obesity (body mass index ≥ 40 kg/m2) * pregnancy * refusal to join the study

Keywords: endotracheal tube cuff postoperative sore throat subglottic airway injury breast cancer
effect of electroacupuncture on benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia

Summary: the study aims to assess the efficacy and safety of electroacupuncture among men with benign prostatic hyperplasia (bph), compared with sham electroacupuncture.


Eligibility criteria:
inclusion criteria: 1. diagnosis of bph in accordance with the european association of urology (eau) guideline; 2. male participants aged between 40 and 80 years; 3. lower urinary tract symptoms (luts) for at least three months; 4. ipss total score ≥8; 5. prostate volume ≥20 ml; 6. urinary peak flow rate (qmax) ≤15 ml/s; 7. voluntary participation in the trial and signed written informed content. exclusion criteria: 1. post-void residual urine volume (pvr) ≥150 ml; 2. acute urinary retention or catheterization for outflow obstruction within the 3 months (except for post-surgical disposable catheterization); 3. prostate cancer or prostate-specific antigen (psa) level ≥4.0 ng/ml; 4. neurogenic lower urinary tract dysfunction; prostatitis; uncontrolled symptomatic urinary tract infections; urethral strictures; bladder diverticula; bladder stones; bladder cancer; history of genitourinary system surgery (prostate, bladder, urethra, etc.); 5. previous acupuncture treatment for bph in the preceding one month, or α-blockers, 5α-reductase inhibitor, muscarinic receptor antagonists, or any other specific medication usage in the previous two weeks unless a stable 5α-reductase inhibitor usage of over three months; 6. severe lung, heart, liver, kidney, metabolic, or mental illness, coagulation dysfunction, or with obvious cognitive dysfunction; 7. installed cardiac pacemaker, allergy to metal, severe fear of acupuncture or unbearable to the stimulation of ea.

Keywords: acupuncture randomized controlled trial lower urinary tract symptoms